Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Roberto D’Amico(University of Modena and Reggio Emilia), Oscar Bertetto(Azienda Ospedaliero Universitaria San Giovanni Battista), Paolo Bruzzi(Alleanza Contro il Cancro), P. Pronzato(Accademia Nazionale dei Lincei), Stefano Cascinu(Vita-Salute San Raffaele University), Francesco Cognetti(Apple (Israel)), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Biagio Agostara, Angelo Di Leo(Hospital of Prato), Maurizio Belfiglio, Annamaria Molino, Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori)
Cited by 57
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k